Authors: Simpson-Yap, Steve, De Brouwer, Edward, Kalincik, Tomas, Rijke, Nick, Hillert, Jan A., Walton, Clare, Edan, Gilles, Moreau, Yves, Spelman, Tim, Geys, Lotte, Parciak, Tina, Gautrais, Clement, Lazovski, Nikola, Pirmani, Ashkan, Ardeshirdavanai, Amin, Forsberg, Lars, Glaser, Anna, McBurney, Robert, Schmidt, Hollie, Bergmann, Arnfin B., Braune, Stefan, Stahmann, Alexander, Middleton, Rodden, Salter, Amber, Fox, Robert J., van der Walt, Anneke, Butzkueven, Helmut, Alroughani, Raed, Ozakbas, Serkan, Rojas, Juan I., van der Mei, Ingrid, Nag, Nupur, Ivanov, Rumen, Sciascia do Olival, Guilherme, Dias, Alice Estavo, Magyari, Melinda, Brum, Doralina, Mendes, Maria Fernanda, Alonso, Ricardo N., Nicholas, Richard S., Bauer, Johana, Chertcoff, Aníbal Sebastián, Zabalza, Arrambide, Georgina, Fidao, Comi, Giancarlo, Peeters, Liesbet
Venue: Neurology
Type: Publication
Abstract: Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Esclerosi múltiple Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Esclerosis múltiple Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Multiple Sclerosis Background and Objectives People with multiple sclerosis (MS) are a vulnerable group for severe coronavirus disease 2019 (COVID-19), particularly those taking immunosuppressive disease-modifying therapies (DMTs). We examined the characteristics of COVID-19 severity in an international sample of people with MS. Methods Data from 12 data sources in 28 cou...
(read more)
Topics: 
Internal medicine
Loading (it may take a couple of seconds)...
Loading (it may take a couple of seconds)...